Clinical trials
Recruiting Glucose Intolerance trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
65 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2006 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 7 |
| 2023 | 5 |
| 2024 | 7 |
| 2025 | 19 |
| 2026 | 13 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 65 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Georgia State University | 2 |
| Johns Hopkins University | 2 |
| The University of Texas Health Science Center at San Antonio | 2 |
| Aarhus University Hospital | 1 |
| Abbott Diabetes Care | 1 |
| AdventHealth Translational Research Institute | 1 |
| Albert Einstein College of Medicine | 1 |
| Applied Science & Performance Institute | 1 |
| Azienda Ospedaliero-Universitaria di Parma | 1 |
| Beneficência Portuguesa de São Paulo | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Glucose Intolerance | 65 |
| Obesity | 17 |
| Prediabetic State | 17 |
| Diabetes Mellitus | 16 |
| Insulin Resistance | 16 |
| Diabetes Mellitus, Type 2 | 15 |
| Overweight | 11 |
| Inflammation | 5 |
| Metabolic Syndrome | 4 |
| Diabetes Mellitus, Type 1 | 3 |
Trials
Showing 76 to 65 of 65. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.